Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913042 | 0.80 | CCR8 (0.42) | MCHR1CCR8OPRM1CCR5ALDH1A1 | |
| SCHEMBL2449927 | 0.80 | CCR8 (0.52) | MCHR1CCR8OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL13850492 | 0.79 | ENPP2 (0.36) | MCHR1OPRM1ARRB1ALDH1A1SIGMAR1 | |
| SCHEMBL2915758 | 0.78 | CCR8 (0.42) | MCHR1CCR8OPRM1CCR5ALDH1A1 | |
| SCHEMBL13850491 | 0.78 | HTR1A (0.40) | MCHR1LMNAOPRM1ALDH1A1SIGMAR1 | |
| SCHEMBL2915410 | 0.78 | MEN1 (0.45) | CCR8LMNAALDH1A1L3MBTL1 | |
| SCHEMBL2942975 | 0.78 | SIGMAR1 (0.48) | MCHR1CCR8OPRM1CCR5SIGMAR1 | |
| SCHEMBL14447691 | 0.76 | EP300 (0.37) | ALDH1A1 | |
| SCHEMBL2481242 | 0.76 | SIGMAR1 (0.43) | MCHR1LMNAOPRM1CCR5SIGMAR1 | |
| SCHEMBL2452541 | 0.75 | CCR8 (0.47) | MCHR1CCR8OPRM1CCR5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | PPARD, PPARG, PPARA | MCHR1 4317/4885CCR8 1387/4885LMNA 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.